Jie Wang
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Emerging Leaders
not ranked
Current Leaders
#2252 pts
All-Time Leaders
#86221 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2017. 12 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase I/II Study of MCLA-129, a Human Anti-EGFR and Anti-c-Met Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors, Evaluating Safety, Pharmacokinetic Characteristics and Antitumor Activity
Phase 2RecruitingBetta Pharmaceuticals Co., Ltd.Study Chair
8
impact
A Study of LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer to Evaluate the Safety, Tolerability and Preliminary Efficacy
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
6
impact
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2RecruitingShanghai Henlius BiotechStudy Chair
2
impact
A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)
Phase 2Not Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
2
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced/Metastatic Solid Tumors
Phase 1Enrolling by InvitationShanghai Henlius Biotech
2
impact
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Phase 3CompletedHutchison Medipharma Limited
2
impact
Efficacy and Safety of First-line mil60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study
Phase 3CompletedBeijing Mabworks Biotech Co., Ltd.
1
impact
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Phase 3CompletedAlpha Biopharma (Jiangsu) Co., Ltd.
0
impact
A Randomized, Open-Label, Multi-center, Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) Monotherapy or HLX43 in Combination With HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2RecruitingShanghai Henlius Biotech
0
impact
Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer
N/ARecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
Phase 2Not Yet RecruitingShanghai Jeyou Pharmaceutical Co., Ltd.
0
impact
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
Phase 3ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
Gumarontinib Combined With Third-generation EGFR-TKI in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Amplification Following EGFR-TKI Treatment Failure.
Phase 2Not Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Phase 1ActiveAstraZeneca
0
impact
A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
Phase 1RecruitingTyligand Bioscience (Shanghai) Limited
0
impact
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.
Phase 1UnknownShanghai Cell Therapy Group Co.,Ltd
0
impact
The Performance of a Pan-cancer Early Detection Model Based on Liquid Biopsy of Various-omics Biomarkers: a Proof of Concept Study
N/ACompletedCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Multi-center, Prospective Observational Study
N/AUnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Study of T790M Mutation Testing in Patient Tissue and Blood With Various Detection Platforms at Hospital Laboratories in Comparison With Central Testing
N/ACompletedAstraZeneca
0
impact
A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change
Phase 1CompletedShanghai Junshi Bioscience Co., Ltd.
0
impact